A Study To Assess the Safety, and Tolerability of Nivolumab + Relatlimab Fixed-Dose Combination (FDC) In Untreated, Unresectable or Metastatic Melanoma Participants In India
Bristol-Myers Squibb
Bristol-Myers Squibb
Jules Bordet Institute
Dana-Farber Cancer Institute
University of Pittsburgh
Centre Hospitalier Régional Metz-Thionville
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest
National University Hospital, Singapore
Państwowy Instytut Medyczny Ministerstwa Spraw Wewnętrznych i Administracji
Institute of Health Information and Statistics of the Czech Republic
Universitaire Ziekenhuizen KU Leuven
Alpha Tau Medical LTD.
Centre Hospitalier Universitaire de Nīmes
Eastern Cooperative Oncology Group
Region Skane
IRCCS Ospedale San Raffaele
Wright State University
Stanford University
University of Auckland, New Zealand